Regenxbio (RGNX) Gross Profit (2014 - 2024)

Regenxbio's Gross Profit history runs 12 years deep, the most recent figure standing at $21.2 million for Q4 2025.

• In Q4 2025, Gross Profit rose 42.45% year-over-year to $21.2 million; the TTM figure through Dec 2025 stood at $145.0 million (up 195.69% YoY), while the FY2025 annual figure was $136.0 million, up 173.24% from the prior year.
• Gross Profit for Q4 2025 stood at $21.2 million, down from $24.0 million in the prior quarter.
• The five-year high for Gross Profit was $375.6 million in Q4 2021, with the low at $6.5 million in Q1 2022.
• The 5-year median for Gross Profit is $15.0 million (2023), against an average of $36.2 million.
• The sharpest annual moves came in 2021 and 2022: Gross Profit jumped 3257.14% in 2021, then tumbled 95.06% in 2022.
• Regenxbio's Gross Profit stood at $375.6 million in 2021, then sank by 95.06% to $18.6 million in 2022, then sank by 40.87% to $11.0 million in 2023, then soared by 35.73% to $14.9 million in 2024, then soared by 42.45% to $21.2 million in 2025.
• Business Quant data shows RGNX's Gross Profit at $21.2 million in Q4 2025, $24.0 million in Q3 2025, and $16.2 million in Q2 2025.